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Abstract
Introduction Adverse exposures in early life may predispose children to cardio-metabolic disease in later life. Metabo-
lomics may serve as a valuable tool to disentangle the metabolic adaptations and mechanisms that potentially underlie these 
associations.
Objectives To describe the acquisition, processing and structure of the metabolomics data available in a population-based 
prospective cohort from early pregnancy onwards and to examine the relationships between metabolite profiles of pregnant 
women and their children at birth and in childhood.
Methods In a subset of 994 mothers-child pairs from a prospective population-based cohort study among pregnant women 
and their children from Rotterdam, the Netherlands, we used LC–MS/MS to determine concentrations of amino acids, non-
esterified fatty acids, phospholipids and carnitines in blood serum collected in early pregnancy, at birth (cord blood), and 
at child’s age 10 years.
Results Concentrations of diacyl-phosphatidylcholines, acyl-alkyl-phosphatidylcholines, alkyl-lysophosphatidylcholines 
and sphingomyelines were the highest in early pregnancy, concentrations of amino acids and non-esterified fatty acids were 
the highest at birth and concentrations of alkyl-lysophosphatidylcholines, free carnitine and acyl-carnitines were the highest 
at age 10 years. Correlations of individual metabolites between pregnant women and their children at birth and at the age of 
10 years were low (range between r = − 0.10 and r = 0.35).
Conclusion Our results suggest that unique metabolic profiles are present among pregnant women, newborns and school aged 
children, with limited intergenerational correlations between metabolite profiles. These data will form a valuable resource 
to address the early metabolic origins of cardio-metabolic disease.
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CV  Coefficient of variation
ESI  Electrospray ionization
FIA  Flow-injection analysis
Free Carn  Free carnitine
HDL  High-density lipoprotein
HPLC  High performance liquid chromatography
LC–MS/MS  Liquid chromatography tandem mass 
spectrometry
LC-PUFA  Long-chain poly-unsaturated fatty acids
LDL  Low-density lipoprotein
Lyso.PC.a  Acyl-lysophosphatidylcholines
Lyso.PC.e  Alkyl-lysophosphatidylcholines
MS  Mass spectrometry
NEFA  Non-esterified fatty acids
PC  Principal component
PCA  Principal component analysis
PC.aa  Diacyl-phosphatidylcholines
PC.ae  Acyl-alkyl-phosphatidylcholines
PL  Phospholipids
SD  Standard deviation
SDS  Standard deviation scores
SM  Sphingomyelines
QC  Quality control
1 Introduction
Cardio-metabolic diseases are of major public health con-
cern (NCD Risk Factor Collaboration 2016, 2017a, b). The 
pathogenesis of these cardio-metabolic diseases involves 
adaptations in metabolic pathways. Thus far, studies mainly 
focused on a small set of conventional biomarkers to assess 
metabolic status and pathways. Recent developments in 
high-throughput technologies and analytical methods have 
enabled the application of metabolomics for detailed char-
acterization of an individual’s metabolic status on a large 
scale (Bictash et al. 2010; Tzoulaki et al. 2014; van Roekel 
et al. 2019). Metabolomics measures a large number of low 
molecular weight metabolites in biological tissues and flu-
ids. The metabolome is the most downstream component of 
biological processes and closely linked to the phenotype. It 
carries information about gene expression as well as life-
style- and environmental factors (Tzoulaki et al. 2014; van 
Roekel et al. 2019). Metabolomics has already been suc-
cessfully applied in large-scale epidemiological studies, 
mainly in adult populations, to identify new biomarkers of 
cardio-metabolic disease status, development and progres-
sion, as well as the underlying pathophysiological mecha-
nisms (Newgard 2017; Rangel-Huerta et al. 2019; Ussher 
et al. 2016).
Accumulating evidence suggests that cardio-metabolic 
diseases might originate in early life. Adverse exposures in 
early life may lead to developmental adaptations in organ 
structure or function, which may predispose these children 
to later cardio-metabolic disease (Gluckman et al. 2008). 
Early-life developmental adaptations in metabolic pathways 
may underlie these associations. Only a limited amount of 
metabolomics studies on the early origins of cardio-meta-
bolic disease have been performed. Most of these studies 
were small and mainly assessed cross-sectional relation-
ships (Hivert et al. 2015; Rauschert et al. 2017a). Also, it is 
unclear whether metabolite profiles correlate between moth-
ers and their children. The application of metabolomics in 
longitudinal birth cohort studies may serve as a valuable 
tool to identify biomarkers of metabolic status, in order to 
disentangle the mechanisms linking adverse exposures in 
early life to cardio-metabolic disease later in life (Hivert 
et al. 2015).
Therefore, in a population-based cohort from early preg-
nancy onwards among 994 mother–child pairs from Rot-
terdam, the Netherlands, we obtained serum concentrations 
of a range of metabolite groups involved in energy metabo-
lism, including amino acids (AA), non-esterified fatty acids 
(NEFA), phospholipids (PL), and carnitines (Carn) in mater-
nal blood in early-pregnancy, and child’s (cord-) blood at 
birth and at age 10 years. We provide a detailed description 
of the data acquisition, processing and data structure and 
examined the relationships between metabolite profiles of 
pregnant women and their children at birth and in childhood.
2  Methods
2.1  Study population
The Generation R Study is a multi-ethnic population-based 
prospective cohort study from fetal life until adulthood in 
Rotterdam, the Netherlands, described in detail previously 
(Kooijman et al. 2016). The study was approved by the Med-
ical Ethical Committee of the Erasmus Medical Center, Uni-
versity Medical Center, Rotterdam (MEC 198.782/2001/31). 
Written informed consent was obtained from all mothers 
at enrollment in the study. Measurement of conventional 
biomarkers of metabolic status in pregnancy and child-
hood has been described previously (Adank et al. 2019; 
Geurtsen et al. 2019; Silva et al. 2019). For metabolomics, 
2,395 blood samples were analyzed from a subsample of 
1041 Dutch mother–child pairs who had their blood drawn 
at birth (cord blood) and at least 1 other time point: early 
pregnancy (mother) or at the age of 10 years (child). A num-
ber of blood samples (n = 157) was excluded during data 
acquisition (e.g. low sample volumes, hemolytic samples) 
and processing (e.g. duplicate samples, high proportion of 
missing values, missing or non-Dutch ethnicity), leaving a 
total of 2,238 blood samples from 994 mother–child pairs 
available for analysis. Of these 994 mother–child pairs, a 
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total of 814 mothers had early pregnancy data available, and 
921 and 503 children had data available at birth and at the 
age of 10 years, respectively. Of all mothers included, 10 had 
a twin pregnancy. Metabolomics data was only available for 
one of the twins. Therefore, mothers with twin pregnancies 
were included only once in the dataset.
2.2  Sample collection and processing
Maternal early-pregnancy non-fasting blood samples were 
obtained at enrollment in the study [median gestational age: 
12.8 weeks (95% range 9.9, 16.9)] by research nurses at 
one of the dedicated research centers (Kruithof et al. 2014). 
Umbilical venous cord blood samples were collected directly 
after birth [median gestational age at birth: 40.3 weeks (95% 
range 36.6, 42.4)] by a midwife or obstetrician. Child’s non-
fasting blood samples were obtained by research nurses at 
the 10-year follow-up visit to the research center [median 
age: 9.8 years (95% range 9.1, 10.6)]. All blood samples 
were transported to the regional laboratory (STAR-MDC), 
spun and stored at − 80 °C for further studies within a maxi-
mum of 4 h after collection. For metabolite measurements, 
blood serum samples were transported on dry ice to the 
Division of Metabolic and Nutritional Medicine of the Dr. 
von Hauner Children’s Hospital in Munich, Germany.
2.3  Metabolite measurements
A targeted metabolomics approach was adopted to determine 
serum concentrations (µmol/L) of AA, NEFA, PL and Carn 
(Hellmuth et al. 2017b). Detailed information is given in 
Supplemental Text S1 and Table S1. Briefly, AA were ana-
lyzed with 1100 high-performance liquid chromatography 
(HPLC) system (Agilent, Waldbronn, Germany) coupled to a 
API2000 tandem mass spectrometer (AB Sciex, Darmstadt, 
Germany) (Harder et al. 2011). IUPAC-IUB Nomenclature 
was used for notation of AA (IUPAC-IUB Joint Commis-
sion on Biochemical Nomenclature 1984). NEFA, PL and 
Carn were measured with a 1200 SL HPLC system (Agilent, 
Waldbronn, Germany) coupled to a 4000QTRAP tandem 
mass spectrometer from AB Sciex (Darmstadt, Germany) 
(Hellmuth et al. 2012; Uhl et al. 2016). The analytical tech-
nique used is capable of determining the total number of 
total bonds, but not the position of the double bonds and 
the distribution of the carbon atoms between fatty acid side 
chains. We used the following notation for NEFA, PL and 
Carn.a:X:Y, where X denotes the length of the carbon chain, 
and Y the number of double bonds. The ‘a’ denotes an acyl 
chain bound to the backbone via an ester bond (‘acyl-’) and 
the ‘e’ represents an ether bond (‘alkyl-’). For analyses, we 
categorized metabolites in to general metabolite groups 
based on chemical structure (AA, NEFA, PC.aa, PC.ae, 
Lyso.PC.a, Lyso.PC.e, SM, Free Carn and Carn.a) and in 
detailed metabolite subgroups based on chemical structure 
and physiological and biological relevance (AA: BCAA, 
aromatic amino acids (AAA), essential AA, non-essential 
AA; NEFA, PC.aa, PC.ae, Lyso.PC.a, Lyso.PC.e and SM: 
saturated, mono-unsaturated, poly-unsaturated; Carn.a: 
short-chain, medium-chain, long-chain).
2.4  Quality control and pre‑processing
To assess the precision of the measurements, six quality 
control (QC) samples per batch were consistently meas-
ured between study samples. After exclusion of outliers, 
the coefficients of variation (CV; SD/mean) for each batch 
(intra-batch) and for all batches (inter-batch) of the QC sam-
ples were calculated for each metabolite. In line with pre-
vious studies (Hellmuth et al. 2017a; Lindsay et al. 2015; 
Rauschert et al. 2017b; Shokry et al. 2019), for each metab-
olite we excluded batches with an intra-batch CV higher 
than 25%. Data on complete metabolites were excluded for 
metabolites with inter-batch CV higher than 35% or if less 
than 50% of the batches passed the QC (i.e. had an intra-
batch CV lower than 25%). To correct for batch effects, the 
participant data at each time point were median corrected 
by dividing the metabolite concentration by the ratio of the 
intra-batch median and the inter-batch median of the QC 
samples (Shokry et al. 2019). In line with previous studies, 
metabolites and participants with more than 50% of missing 
values were excluded (Hellmuth et al. 2017a; Shokry et al. 
2019). Missing values in other participants were imputed 
using the Random Forest algorithm (R package missForest), 
which has been shown to perform well with MS data (Wei 
et al. 2018).
2.5  Statistical analysis
First, we calculated the sum of individual metabolite con-
centrations per general and detailed metabolite group and 
per time point. In order to explore the variability of the 
metabolites between participants and between time points, 
we obtained the median (95% range) for the individual 
metabolites and the summed metabolite concentrations per 
general and detailed metabolite group per time point. To 
enable comparison between time points, only metabolites 
that were present at each time point were included in the 
summed variables. Second, we explored the dimensional-
ity of the data, by conducting principal component analyses 
(PCA) at each time point separately. As log transformations 
did not sufficiently normalize the metabolite concentrations, 
we used square root transformations to normalize metabo-
lite concentrations. These normalized metabolite concentra-
tions were subsequently standardized by calculating standard 
deviation scores [SDS; (observed value − mean)/SD]. Third, 
as we considered PCA not informative for describing the 
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information contained in our dataset, we further explored 
the correlation structure of the data by calculating pairwise 
Pearson’s correlations coefficients between all individual 
metabolites within each time point and between individual 
metabolites at different points. These correlations within and 
between time points were visualized using two circos plots 
(R package circlize) (Chung et al. 2018; Gu et al. 2014). To 
facilitate presentation, the first plot only includes correlation 
coefficients < − 0.15 and > 0.15. To display correlation coef-
ficients that are at least of weak magnitude, the second plot 
displays correlation coefficients < − 0.30 and > 0.30 (Hinkle 
et al. 2003). To obtain further insight in possible metabolic 
pathways, we additionally presented correlations between 
metabolites within a time point as correlation networks, 
as correlations between metabolites were strongest within 
time points (Rosato et al. 2018). To provide a numerical 
summary of the strength of the correlations, we addition-
ally constructed heatmaps of the median absolute correlation 
coefficients within general and detailed metabolite groups 
and between general and detailed metabolite groups at each 
of the time points separately. We calculated the correlation 
coefficients for correlations between individual metabolites 
at different time points. Correlations of 0–0.29, 0.3–0.49, 
0.5–0.69, 0.7–0.89, and 0.9–1.0 were considered to be very 
low, low, moderate, high and very high, respectively (Hinkle 
et al. 2003). As sex differences in metabolite concentrations 
may exist (Ellul et al. 2019), we repeated steps one and three 
stratified by child’s sex. The statistical analyses were per-
formed using R version 3.3.4 (R Foundation for Statistical 
Computing) (R Core Team 2015).
3  Results
3.1  Description of the study population
Table 1 provides general characteristics of the study popula-
tion. Of the 994 mother–child pairs with data available, 125 
(12.6%), 494 (49.7%) and 375 (37.7%) had data available at 
1, 2, or 3 time points, respectively.
3.2  Variability
Data was available on a total of 196 metabolites, of which 
195 metabolites in early pregnancy, 194 metabolites at 
birth and 181 metabolites at child’s age 10 years. Descrip-
tive information is provided in Supplemental Table S2. Fig-
ure 1 shows that the summed metabolite concentration for 
each general metabolite group varied considerably by time 
point. Summed concentrations of PC.aa, PC.ae, Lyso.PC.e 
and SM were highest in maternal blood in early pregnancy, 
compared to the other time points. Summed concentrations 
of AA and NEFA were highest in children at birth, whereas 
summed concentrations of Lyso.PC.a, Free Carn and Carn.a 
were highest in children of age 10. Supplemental Table S2 
gives the summed concentrations of the detailed metabolite 
subgroups, which followed similar patterns. Supplemental 
Fig. S1 shows that the summed metabolite concentrations 
did not differ by child’s sex.
3.3  Dimensionality
Table 2 shows the number of components (PCs) required 
to explain percentages of cumulative variance at each time 
point. At each time point, a relatively high number of PCs 
was needed to explain > 85% of the variance. The obtained 
PCs did not clearly represent specific metabolic pathways 
(Supplemental Figs. S2–S4).
3.4  Correlation structure
Figure 2 provides an overview of the correlations between 
individual metabolite concentrations within general metabo-
lite groups (outer circle), between metabolites concentra-
tions in different general metabolite groups (inner circle) 
and metabolite concentrations at different time points (lines 
going through the middle of the circle). Figure 2a shows all 
correlations lower than − 0.15 or higher than 0.15, whereas 
Fig. 2b shows all correlations lower than − 0.30 or higher 
than 0.30. At all time points, relatively high correlations 
were observed of individual metabolites within general 
metabolite groups and between individual metabolites 
from the different PL groups (PC.aa, PC.ae, Lyso.PC.a, 
Lyso.PC.e, and SM), between AA and Carn.a, and between 
NEFA and Carn.a. These correlations were mainly of posi-
tive direction, except some of the correlations between AA 
and Carn.a. In children of age 10 years only, some of the 
AA were negatively correlated with NEFA. Presentation of 
these correlations within pregnant women, children at birth 
and children at age 10 years as correlation networks showed 
the strongest correlations for individual metabolites within 
general metabolite groups (Supplemental Fig. S5).
To provide further insight into the strength of these corre-
lations, Fig. 3a–c summarizes the correlations as the median 
absolute correlations of individual metabolites within gen-
eral and detailed metabolite groups (diagonal) per time 
point. The median absolute correlations between general 
and detailed metabolite groups per time point are shown 
off-diagonal. Median absolute correlations within general 
and detailed metabolite groups at the same time point were 
low to high, and ranged between r = 0.27 and r = 0.92. The 
strength of these within-group median correlations differed 
by detailed metabolite subgroup, with BCAA, mono-unsat-
urated NEFA, mono-unsaturated PC.aa, mono-unsaturated 
PC.ae, saturated Lyso.PC.e, mono-unsaturated SM and 
long-chain Carn.a generally having the highest median 
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correlations within their respective general groups. Median 
absolute correlations between subgroups of different metab-
olite groups were very low, except for correlations between 
NEFA detailed subgroups and medium-chain Carn.a in 
early pregnancy (r ranging between 0.24–0.34) and at age 
10 years (r ranging between 0.23–0.44), between BCAA and 
AAA and short-chain Carn.a in early pregnancy (r = 0.26 
and r = 0.33, respectively) and at age 10 years (r = 0.30 and 
r = 0.25, respectively), and between BCAA and short-chain 
Carn.a (r = 0.33) at birth.
Table  3 shows correlations of individual metabo-
lites between each of the time points. For presentation 
purposes, this table only gives the 30 strongest correla-
tions at each combination of time points, all correlations 
given in Supplemental Table S3. Correlations between 
early pregnancy and child’s metabolites at birth mainly 
included Free Carn, and Carn.a, and some long chain- and 
very long chain NEFA and some mainly non-essential 
AA. Correlations between early pregnancy and child age 
10 years included a few AA and some PC.aa. In children, 
metabolites correlated between birth and age 10 years 
mainly included phospholipids. Almost all correlations 
were very weak, except the correlations between early 
pregnancy and birth Free Carn (r = 0.35) and Carn.a C9:0 
(r = 0.32). Supplemental Figs. S6 and S7 show that the 
correlations between individual metabolites and median 
absolute correlations, respectively, were similar for boys 
and girls.
Table 1  General characteristics of the study population
Values represent mean (SD), median (95% range) or number of participants (valid %)
NA not applicable
a Represents gestational age in weeks
b Represents age in years
Total sample Time point
Mother early pregnancy Child at birth Child age 10 years
n = 994 n = 814 n = 921 n = 503
(Gestational-) age at blood sample, median (95% range), 
weeks/years
NA 12.8 (9.8, 16.9)a 40.3 (36.6, 42.4)a 9.8 (9.1, 10.6)b
Maternal characteristics
 Age, mean (SD), years 31.5 (4.2) 31.4 (4.1) 31.5 (4.1) 31.9 (3.9)
 Education level, n (%)
  Primary 21 (2.1) 15 (1.9) 20 (2.2) 6 (1.2)
  Secondary 342 (34.7) 285 (35.2) 324 (35.4) 165 (32.9)
  Higher 623 (63.2) 509 (62.9) 570 (62.4) 330 (65.9)
 Pre-pregnancy BMI, median (95% range), kg/m2 22.5 (18.5, 33.3) 22.6 (18.5, 33.3) 22.5 (18.5, 33.5) 22.4 (18.6, 33.4)
 Early pregnancy glucose, mean (SD), mmol/L 4.4 (0.8) 4.4 (0.8) NA NA
 Early pregnancy total cholesterol, mean (SD), mmol/L 4.9 (0.8) 4.7 (0.8) NA NA
 Early pregnancy triglycerides, median (95% range), 
mmol/L
1.2 (0.7, 2.5) 1.3 (0.7, 2.5) NA NA
 Early pregnancy HDL-cholesterol, mean (SD), mmol/L 1.8 (0.3) 1.8 (0.3) NA NA
 Early pregnancy LDL-cholesterol, mean (SD), mmol/L 2.5 (0.7) 2.5 (0.7) NA NA
Child’s characteristics
 Gestational age at birth, median (95% range), weeks 40.3 (36.4, 42.4) 40.3 (36.1, 42.4) 40.3 (36.6, 42.4) 40.3 (37.1, 42.4)
 Birth weight, median (95% range), g 3545 (2465, 4546) 3550 (2470, 4549) 3548 (2500, 4560) 3560 (2591, 4509)
 Sex, male (%) 532 (53.5) 441 (54.2) 497 (54.0) 259 (51.4)
 Body mass index at age 10 years, median (95% range), 
kg/m2
16.7 (14.0, 22.2) NA NA 16.6 (14.1, 21.8)
 Glucose at age 10 years, mean (SD), mmol/L 5.3 (0.9) NA NA 5.3 (0.9)
 Total cholesterol at age 10 years, mean (SD), mmol/L 4.3 (0.6) NA NA 4.3 (0.6)
 Triglycerides at age 10 years, median (95% range), 
mmol/L
0.9 (0.4, 2.4) NA NA 0.9 (0.4, 2.4)
 HDL-cholesterol at age 10 years, mean (SD), mmol/L 1.5 (0.3) NA NA 1.5 (0.3)
 LDL-cholesterol at age 10 years, mean (SD), mmol/L 2.3 (0.6) NA NA 2.3 (0.6)
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4  Discussion
We described the data acquisition, processing and struc-
ture of the metabolomics data available in the Generation 
R Study and assessed the relationships between metabolite 
profiles of pregnant women and their children at birth and 
in childhood. Metabolite concentrations vary considerably 
between pregnant women and their children at birth and at 
the age of 10 years. The individual metabolites correlate 
within groups of metabolites with similar chemical struc-
tures, but to a lesser extent between groups of metabo-
lites with different chemical structures. The correlations 
of individual metabolites between pregnant women and 
their children at birth and age 10 years are relatively low.
4.1  Interpretation of main findings
Metabolomics studies targeting cardio-metabolic diseases 
have already been successfully applied in adults (Newgard 
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Fig. 1  Median metabolite concentrations by metabolite group and 
time point. Values represent the median (95% range) of the sum of 
the individual metabolite concentrations in each of the metabolite 
groups, by time point. Sums only include metabolites with data at 
all time points, and therefore do not include concentrations of lyso.
PC.a.C20.2, PC.aa.C32.3, PC.aa.C34.5, PC.aa.C36.0, PC.aa.C38.2, 
PC.aa.C40.3, PC.ae.C34.4, SM.a.C30.1, SM.a.C35.0, SM.a.C37.1, 
SM.a.C38.3, SM.a.C39.2, SM.a.C40.5, SM.a.C42.4, SM.a.C44.6, 
SM.e.C36.2, and SM.e.C40.5. SM includes SM.a plus one SM.e. AA 
amino acids, PC.aa diacyl-phosphatidylcholines, PC.ae acyl-alkyl-
phosphatidylcholines, Lyso.PC.a acyl-lysophosphatidylcholines, 
Lyso.PC.e alkyl-lysophosphatidylcholines, SM sphingomyelines, 
NEFA non-esterified fatty acids, Free Carn free carnitine, Carn.a 
acyl-carnitines
Table 2  Number of components 
required to explain percentages 
of cumulative proportions of 
variance at each time point
Values represent the number of principal components (PCs) derived from principal component analyses 
required to explain 50, 75, 85, 95, and 99.5%, respectively, of the variances of the data at each of the time 
points
Time point Number of 
metabolites
Number of PCs
50% 75% 85% 95% 99.5%
Mother early pregnancy 195 3 15 35 88 163
Child at birth 194 4 21 46 101 169
Child age 10 years 181 6 27 50 98 157
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2017; Rangel-Huerta et al. 2019; Ussher et al. 2016), but 
only a limited number of metabolomics studies have been 
performed on the early origins of these diseases (Hivert 
et al. 2015; Rauschert et al. 2017a). We obtained intergen-
erational metabolomics data at three different time points 
during pregnancy and postnatal life, that may provide more 
detailed insights in the early origins of cardio-metabolic 
disease, the underlying mechanisms and identify potential 
novel biomarkers.
Maternal metabolic profile during pregnancy might influ-
ence fetal metabolic profile, either directly through placen-
tal transfer, or indirectly by influences on hormone levels 
or placental function (Hivert et al. 2015). Maternal blood 
metabolite concentrations generally tend to decrease across 
pregnancy, likely reflecting increased circulating volume, 
tissue biosynthesis and placental uptake (Lindsay et al. 
2015). Fetal metabolite concentrations are the result of both 
placental transfer and endogenous synthesis. Concentra-
tions of AA, Carn and NEFA, particularly long-chain poly-
unsaturated fatty acids (LC-PUFA), tend to be higher in fetal 
blood than in maternal blood (Larque et al. 2011; Regnault 
et al. 2002; Schmidt-Sommerfeld et al. 1985). This might 
be indicative of an active transport mechanism across the 
placenta or increased fetal synthesis. Although the large time 
differences between the metabolite measurements in our 
study should be noted and preclude direct conclusions about 
placental transfer, our observation that the summed concen-
trations of AA, NEFA and Carn.a were higher in cord blood 
than in maternal early pregnancy blood is in line with these 
previous studies. The lower PL concentrations observed 
in cord blood in comparison to maternal early pregnancy 
blood might be explained by the fact that PL do not cross 
the placenta, but are hydrolyzed to NEFA that in turn cross 
the placental barrier (Herrera and Ortega-Senovilla 2010; 
Larque et al. 2011; Rice et al. 1998). Relatively high correla-
tions between individual metabolites within known general 
and detailed metabolite subgroups in pregnant women as 
well as in cord blood were observed, as expected from the 
shared precursors and biosynthesis pathways. However, cor-
relations of individual metabolites between these two time 
points were relatively weak. These results are in line with 
those from a multi-ethnic study among 1600 participants 
that showed mostly weak correlations of these metabolites 
between maternal blood at 28 weeks of gestation and cord 
blood (Lowe et al. 2017). In our study, there is a large time 
difference between the metabolite measurements in moth-
ers and newborns. Therefore, the relatively low correlations 
between maternal and cord blood metabolites might result 
from changes in metabolism in both pregnant women and 
the fetus that occur throughout pregnancy (Herrera and 
Ortega-Senovilla 2010; Lindsay et al. 2015). In addition, 
placental transfer of nutrients throughout pregnancy is 
tightly regulated by various transport mechanisms to ensure 
stable fetal metabolite concentrations at the expense of vari-
ations in maternal metabolite concentrations (Larque et al. 
2013; Rossary et al. 2014). The relatively high correlations 
for carnitines in our study might be explained by the main 
source of carnitines for the fetus being placental transfer, 
rather than endogenous synthesis (Alexandre-Gouabau et al. 
2013). Thus, individual metabolite concentrations correlate 
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Fig. 2  Circos plots of correlations between individual metabolite 
concentrations. Lines represent Pearson’s correlation coefficients 
between the individual metabolite concentrations within metabolite 
groups (outer circle), between metabolite groups (inner circle) and 
between time points (lines going through the middle of the circle). 
Red lines represent positive correlations and blue lines represent neg-
ative correlations. The brightness of the lines indicates the strength 
of the correlations, with brighter colors for stronger correlations. a 
Shows only correlation coefficients lower than − 0.15 and higher than 
0.15 and b shows only correlation coefficients lower than − 0.30 and 
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lysophosphatidylcholines, SM sphingomyelines, Free Carn free carni-
tine, Carn.a acyl-carnitines
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within mothers and newborns, but barely between mothers 
and newborns. This might result from changes in maternal 
and fetal metabolism throughout pregnancy and from tightly 
regulated active trans-placental transport mechanisms result-
ing in distinct metabolite profiles in pregnant women and 
their children at birth.
Less is known about the metabolite profiles from birth 
throughout childhood and the influence of maternal metabo-
lite profiles in pregnancy on these profiles. A study among 
127 children from Sweden showed that concentrations 
of conventional lipids, including total cholesterol, LDL 
cholesterol and HDL cholesterol increased between the age 
of 6 months and 4 years, whereas triglyceride concentra-
tions decreased (Ohlund et al. 2011). A study among 500 
children and adolescents aged 0 to 19 years observed that 
concentrations of AA, NEFA, and Carn.a dropped after the 
neonatal period. However, some of these Carn.a increased 
again from the age of 7 years and returned to neonatal con-
centrations at age 19 years (Teodoro-Morrison et al. 2015). 
A large familial resemblance in metabolite concentrations 
has been suggested, which seems to be largely genetic (Dra-
isma et al. 2013; Kettunen et al. 2016; Rueedi et al. 2014). In 
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Fig. 3  Heatmaps of median absolute correlation of individual 
metabolites within and between metabolite groups by time point. 
Values represent median absolute correlation coefficients of indi-
vidual metabolite concentrations within metabolite groups (diago-
nal) and between metabolite groups (off-diagonal) by time point. 
Mono-unsaturated lyso.PC.e, saturated SM and Free Carn include 1 
metabolite, resulting in a correlation coefficient of 1 for within-group 
correlations. For child at birth, no data on saturated SM is available. 
AA amino acids, BCAA branched-chain amino acids, AAA aromatic 
amino acids, NEFA non-esterified fatty acids, PC.aa diacyl-phos-
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lines, SM sphingomyelines, Free Carn free carnitine, Carn.a acyl-
carnitines, Sat. Saturated, Unsat. Unsaturated
A population-based resource for intergenerational metabolomics analyses in pregnant women…
1 3
Page 9 of 14    43 
cross-sectional studies, correlations of metabolites between 
parents and their offspring vary strongly, ranging from 
weak to relatively strong (Ellul et al. 2019; Halvorsen et al. 
2015; Ohlund et al. 2011). Partly in line with these previ-
ous studies, we observed that AA and NEFA concentrations 
were lower in childhood as compared to cord blood sam-
ples, whereas concentrations of PL and Carn were higher 
in childhood. However, the correlations between individual 
metabolite concentrations of children at birth and at the age 
of 10 years as well as between mothers in early pregnancy 
and their children at the age of 10 years were very weak. 
This might be explained by the large timespan between the 
measurements. Also, previous research has indicated that 
metabolite concentrations are highly influenced by nutri-
tional factors, physical activity and the gut microbiome 
(Hellmuth et al. 2019; Lau et al. 2018; Palmnas et al. 2018; 
Pedersen et al. 2016; Wang et al. 2011). Differences in these 
factors between mothers and their children and over time 
might explain the weak correlations between different time 
points. Previous studies observed sex differences in metabo-
lite concentrations in both children and adults (Ellul et al. 
2019; Teodoro-Morrison et al. 2015). We did not observe 
metabolite concentrations to vary between the sexes. This 
could be explained by the relatively young age of the par-
ticipants, as sex differences in metabolite concentrations 
have been shown to be more pronounced in adolescence and 
adulthood (Ellul et al. 2019; Teodoro-Morrison et al. 2015). 
Thus, correlations between individual metabolites between 
pregnant women and their children at school-age and within 
children over time are very low. This might suggest strong 
influences of external factors and limited intergenerational 
correlations of metabolite profiles.
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We provided the first explorative analyses of a unique 
large longitudinal dataset consisting of metabolomics data 
of pregnant women and their children at birth and in child-
hood, and studied correlations between a large number 
of metabolites at these different time points. Not much is 
known yet about the correlations of metabolites between 
pregnant women and their children and the metabolite pro-
files in children from birth until childhood. We observed 
relatively low correlations of metabolite concentrations 
between time points. We explored whether offspring sex 
affected these correlations as this is an important base-
line characteristic which has been suggested to influence 
metabolite profiles in children and adults, but this did not 
affect our findings. Other maternal and childhood fac-
tors are likely to influence metabolite profiles in pregnant 
women, and the development of metabolites profiles from 
birth until childhood. Further studies are needed to obtain 
detailed insight into the influence of maternal and off-
spring socio-demographic, lifestyle and physical factors on 
the stability of metabolites profiles in pregnancy and from 
birth throughout childhood. Future studies using these data 
should take into account the correlations of metabolites 
within the same metabolite group. PCA, a data reduction 
approach commonly used in metabolomics, showed that 
the data were highly dimensional. This indicates that the 
variability in the data is difficult to capture in a lower num-
ber of components and that each metabolite contributes 
unique information. In addition, the obtained components 
did not describe specific metabolic pathways. There-
fore, we do not consider the PCs informative in describ-
ing the information contained in this dataset. Given the 
high dimensionality of the data and the relatively high 
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correlation of metabolites within metabolite groups, it 
seems that future studies focused on relating these data to 
exposures and outcomes of interest should analyze the data 
per individual metabolite and per metabolite group with 
structural, physiological and biological relevance. In addi-
tion, correlation networks based on correlations between 
individual metabolites or more advanced pathway analysis 
may be useful for identifying metabolic pathways involved 
in these associations. Due to the longitudinal nature of the 
data and the large amount of data on relevant exposures 
and outcomes available in the cohort, these data will form 
an important population-based resource for future metabo-
lomics analyses on the developmental origins of cardio-
metabolic disease.
4.2  Methodological considerations
We obtained metabolomics data in a subgroup of the cohort, 
which consists of Dutch, relatively high educated and 
healthy participants, as compared to the full cohort (Kooij-
man et al. 2016). This may affect the generalizability of our 
sample to the full cohort and the general population. We 
adopted a targeted metabolomics approach, which enabled 
us to study absolute metabolite concentrations of metabo-
lites known a priori to be relevant for obesity and cardio-
metabolic disease. However, the targeted design might also 
be a limitation in future association studies, as relevant bio-
logical pathways might be missed. The blood samples used 
in our study were non-fasting and taken during non-fixed 
Table 3  Correlations of individual metabolite concentrations between time points, subset of 30 strongest correlations
Values represent Pearson’s correlation coefficients (r), and corresponding p-values and number of participants for correlations between metabo-
lites at different time points. For presentation purposes, only the 30 strongest correlations at each combination of time points were presented. A 
complete list of correlations is given in Supplemental Table S3
A. Mother early pregnancy—child at birth B. Mother early pregnancy—child age 10 years C. Child at birth—child age 10 years
Metabolite n r p-value Metabolite n r p-value Metabolite n r p-value
Free Carn 749 0.35 < 0.001 Free Carn 413 0.24 < 0.001 Cit 457 0.24 < 0.001
Carn.a C9:0 749 0.32 < 0.001 PC.aa C36:6 413 0.23 < 0.001 SM.a C34:2 457 0.21 < 0.001
Carn.a C8:1 749 0.28 < 0.001 Carn.a C14:2 413 0.22 < 0.001 lyso.PC.a C22:6 457 0.20 < 0.001
Carn.a C4:0 749 0.26 < 0.001 Cit 413 0.21 < 0.001 SM.a C42:6 457 0.20 < 0.001
NEFA C26:0 749 0.24 < 0.001 Orn 413 0.21 < 0.001 His 457 0.19 < 0.001
Gly 749 0.22 < 0.001 Asn 413 0.17 < 0.001 Carn.a C4:0 457 0.19 < 0.001
Carn.a C10:1 749 0.22 < 0.001 PC.aa C38:4 413 0.17 0.001 PC.aa C38:6 457 0.18 < 0.001
Carn.a C15:0 749 0.22 < 0.001 PC.aa C38:6 413 0.17 < 0.001 PC.ae C32:2 457 0.18 < 0.001
Carn.a C3:0 749 0.21 < 0.001 NEFA C24:4 413 0.16 0.001 SM.a C32:2 457 0.18 < 0.001
Cit 749 0.20 < 0.001 PC.aa C38:0 413 0.16 0.001 Free Carn 457 0.18 < 0.001
NEFA C20:5 749 0.20 < 0.001 PC.aa C36:5 413 0.15 0.002 PC.aa C36:5 457 0.17 < 0.001
Carn.a C8:0 749 0.20 < 0.001 PC.ae C34:3 413 0.15 0.002 PC.aa C38:0 457 0.17 < 0.001
NEFA C22:6 749 0.19 < 0.001 NEFA C20:5 413 0.14 0.004 PC.ae C34:1 457 0.17 < 0.001
Carn.a C2:0 749 0.19 < 0.001 NEFA C24:5 413 0.14 0.004 Orn 457 0.16 < 0.001
Carn.a C14:2 749 0.19 < 0.001 PC.aa C40:6 413 0.14 0.003 PC.aa C43:6 457 0.16 0.001
His 749 0.18 < 0.001 PC.aa C43:6 413 0.14 0.005 PC.ae C32:0 457 0.16 0.001
Carn.a C10:0 749 0.18 < 0.001 PC.ae C36:5 413 0.14 0.004 NEFA C26:1 457 0.15 0.001
Carn.a C18:2 749 0.18 < 0.001 PC.ae C40:0 413 0.14 0.005 NEFA C26:2 457 0.15 0.001
Carn.a C20:3 749 0.18 < 0.001 SM.a C35:1 413 0.14 0.005 PC.ae C38:6 457 0.15 0.001
Carn.a.C20.4 749 0.18 < 0.001 Carn.a C4:0 413 0.14 0.004 PC.ae C42:3 457 0.15 0.001
Pro 749 0.17 < 0.001 Carn.a C15:0 413 -0.14 0.004 SM.a C33:1 457 0.15 0.001
PC.ae C42:4 749 0.17 < 0.001 Carn.a C16:0 413 0.14 0.004 Carn.a C8:1 457 0.15 0.002
lyso.PC.a C22:6 749 0.17 < 0.001 Ala 413 0.13 0.007 NEFA C20:5 457 0.14 0.003
Carn.a C12:0 749 0.17 < 0.001 Thr 413 0.13 0.007 NEFA C24:1 457 0.14 0.003
NEFA C26:1 749 0.16 < 0.001 PC.ae C30:0 413 0.13 0.007 NEFA C24:4 457 0.14 0.003
PC.aa C44:12 749 0.16 < 0.001 PC.ae C38:0 413 0.13 0.009 PC.ae C42:5 457 0.14 0.002
Ala 749 0.15 < 0.001 PC.ae C40:1 413 0.13 0.009 PC.ae C42:6 457 0.14 0.003
Phe 749 0.15 < 0.001 PC.ae C42:5 413 0.13 0.008 SM.a C32:1 457 0.14 0.004
PC.aa C38:6 749 0.15 < 0.001 Carn.a C16:0.Oxo 413 0.13 0.008 SM.a C36:2 457 0.14 0.002
lyso.PC.a C20:5 749 0.15 < 0.001 Gln 413 0.12 0.018 NEFA C22:3 457 0.13 0.006
 E. Voerman et al.
1 3
  43  Page 12 of 14
times of the day for logistic and ethical reasons (relatively 
young age of the children). Metabolite concentrations are 
dependent on fasting status. Fasting blood samples are usu-
ally preferred, as they are more reliable over time (Carayol 
et al. 2015). The use of non-fasting blood samples in our 
study might influence precision and power to detect associa-
tions of interest. However, non-fasting blood samples appear 
to be more informative of metabolic status throughout the 
day. Also, non-fasting lipids have been shown to perform 
equally or even better than fasting lipids in predicting the 
risk of cardiovascular disease (Nordestgaard et al. 2016). We 
therefore still consider non-fasting metabolite concentrations 
to be of interest. Due to the longitudinal design of the study, 
we were able to measure metabolite concentrations at 3 dif-
ferent time points during pregnancy and early postnatal life. 
However, due to the large time intervals between the blood 
samples and differences in the nature of the blood samples, 
small differences in procedures and handling of the blood 
samples may exist. As previous studies showed that differ-
ent pre-storage temperatures and durations only minimally 
affected measured concentrations of most metabolites, we 
consider it unlikely that this strongly influenced our results.
5  Conclusions
Metabolite concentrations vary between pregnant women 
and their children at birth and at the age of 10 years. Cor-
relations of individual metabolites between pregnant women 
and their children at birth and in childhood are relatively 
low. This may suggest that unique metabolic profiles are 
present among pregnant women, newborns and school aged 
children, with limited intergenerational correlations between 
metabolite profiles. These data are an important population-
based resource for future metabolomics analyses to address 
the early origins of cardio-metabolic disease.
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